Oligo Safety Group Recommends Continued Focus on Hybridization-Dependent Off-Target Effects
March 25, 2010
Oligo Safety Group Recommends Continued Focus on Hybridization-Dependent Off-Target Effects
Although most of the toxicities related to oligonucleotide-based therapeutics observed in past years relate to the chemistry of the oligos, improvements in chemical modifications and delivery technologies have increased the potential for hybridization-dependent off-target effects.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Tools & Techniques: TALENs for miRNA Manipulation; CLASH for miRNA-Target Analysis; and More
May 21, 2013 / Gene Silencing News - Alnylam Releases Proof-of-concept Data on Preclinical Porphyria Drug
May 21, 2013 / Gene Silencing News - IP Update: Recent Patents, Patent Applications Awarded to Alnylam, Novartis, Tekmira, and More
May 21, 2013 / Gene Silencing News - Gradalis Releases New Clinical Data on Cancer Vaccine
May 16, 2013 / Gene Silencing News - Former Traversa Exec Forms New Company to Develop Oligo-modification Tech
May 16, 2013 / Gene Silencing News